Introduction {#Sec1}
============

Hemophagocytic syndrome (HPS) is a serious disorder characterized by persistent high-grade fever, hepatosplenomegaly, pancytopenia, abnormal coagulopathy, and hemophagocytosis by macrophages in the bone marrow, spleen, liver, and lymph node \[[@CR1]--[@CR3]\]. The cause of HPS has been supposed to be hyper-activation of macrophages, T cells, and natural killer (NK) cells, hypercytokinemia caused by these activated cells, and further activation of these cells, that is, a malignant loop of excess cell activation and cytokine production \[[@CR2], [@CR4], [@CR5]\]. Cytokines involved in HPS include interferon gamma (IFN-γ), macrophage colony-stimulating factor (M-CSF), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6), IL-10, IL-12, and IL-18 \[[@CR4]--[@CR10]\]. HPS mostly develops secondarily to various infections, malignancies including hematological neoplasm, and autoimmune diseases \[[@CR2], [@CR11]\].

Among these secondary HPS, the incidence of lymphoma-associated hemophagocytic syndrome (LAHS) is relatively high and its prognosis is poor compared with that of malignant lymphoma without HPS \[[@CR11]--[@CR16]\]. Although early diagnosis and appropriate chemotherapy for LAHS are important, LAHS at an early stage does not always fulfill the diagnostic criteria proposed by the International Histiocyte Society in 2004 (HLH-2004) \[[@CR3]\]. In virus-associated hemophagocytic syndrome (VAHS), IFN-γ is a key cytokine that activates macrophages and transforms them into hemophagocytic cells \[[@CR17]--[@CR19]\]. The blood level of IFN-γ is elevated, and consequently, this cytokine could be a diagnostic marker for VAHS if rapid measurement is available. In LAHS, IFN-γ may also play an important role; however, the exact key cytokine in LAHS remains controversial \[[@CR20]--[@CR22]\]. Therefore, it is a pressing need to identify early markers for LAHS. For this purpose, we have screened multiple chemokines/cytokines in the blood of patients with LAHS.

Another problem in identifying these markers is the assay system for cytokines. Sandwich enzyme-linked immunosorbent assay (ELISA) has been a gold standard technique for the measurement of cytokines; however, ELISA has some disadvantages in terms of its employment as a routine laboratory test in a hospital. ELISA is time-consuming and expensive, and requires a large amount of serum. In recent years, a newly developed technique, cytometric bead array (CBA) \[[@CR23]--[@CR27]\], has been introduced in the field of clinical medicine \[[@CR19], [@CR28]--[@CR32]\]. This assay system has resolved the majority of faults of ELISA. CBA has enabled us to screen cytokine markers for LAHS and rapidly obtain the result of multiple cytokine concentrations in a small amount of specimen.

Design and methods {#Sec2}
==================

Patients {#Sec3}
--------

Fifteen adult lymphoma patients with LAHS and 18 without LAHS were enrolled in the present study from May 2007 to January 2010 in Kobe City Medical Center General Hospital. The present study was a retrospective analysis of a single institutional clinical study designated as "Cytokine Profile in Lymphoma-Associated Hemophagocytic Syndrome," which had been approved by an institutional review board. Written informed consent was obtained from all patients. The diagnosis of LAHS was made according to the criteria of Tsuda \[[@CR1]\] with some modifications: (1) high fever for more than a week; (2) unexplained progressive cytopenia affecting at least two cell lineages; (3) bone marrow showing mature histiocytes comprising more than 3 % of nucleated cells with prominent hemophagocytosis and/or hemophagocytosis in the liver, spleen, or lymph node; and (4) definite diagnosis of malignant lymphoma (modified by us). Of the LAHS patients in the present study, nine had B-cell lymphomas (B-LAHS) and six had T-cell/natural killer cell lymphomas (T/NK-LAHS). As a control, 18 lymphoma patients without LAHS (non-LAHS) were analyzed. Of these patients, 16 had B-cell lymphomas and two T/NK-cell lymphomas. The diagnosis of malignant lymphoma was made according to the 2008 WHO Classification \[[@CR33]\]. All patients diagnosed with LAHS during the above mentioned period were enrolled in the present study. Regarding non-LAHS patients, 18 patients admitted during the same period were randomly selected for the examination of the cytokine profile. Patient characteristics and laboratory data are shown in Table [1](#Tab1){ref-type="table"}. Other controls included 20 healthy volunteers and nine sepsis patients with hematologic malignancies (three patients with B-cell type acute lymphoblastic leukemia, three myelodysplastic syndrome, one B-cell lymphoma, one T/NK-cell lymphoma, and one multiple myeloma).Table 1Characteristics of patients and their laboratory dataLAHS (*n* = 15)Non-LAHS (*n* = 18)*P* valueUnderlying NHLB 9, T/NK 6B 16, T/NK 2NS(DLBCL 5, IVL 4, AITL 1, ENKL 1, PTCL 4)(DLBCL 9, FL 5, MCL 2, PTCL 2)Age21--78 (61)50--86 (65)NSStageStage IV 15Stage IV 11, stage I--III 7\<0.05IPIHigh 14, high-intermediate 1High 6, high-intermediate 4\<0.05B symptom(+) 15(+) 7, (−) 11\<0.001BM invasion(+) 15(+) 11\<0.05WBC (×10^9^/L)0.4--8.2 (4.5)2.1--11.2 (6.65)\<0.005Hb (g/dL)7.5--10.4 (8.3)7.7--17.0 (13.7)\<0.001PLT (×10^9^/L)8--142 (56)84--499 (203)\<0.001LDH (IU/L)210--4,021 (838)109--3,985 (218)\<0.002sIL-2R (U/mL)795--53,900 (13,870)149--8,930 (1,385)\<0.001Ferritin (ng/mL)579--36,555 (7,287)80--3,038 (1,674)\<0.001*Abbreviations*: *LAHS* lymphoma-associated hemophagocytic syndrome, *NHL* non-Hodgkin's lymphoma, *IPI* International Prognostic Index, *BM* bone marrow, *WBC* white blood cell, *Hb* hemoglobin, *PLT* platelet, *LDH* lactate dehydrogenase, *sIL-2R* soluble interleukin-2 receptor, *DLBCL* diffuse large B-cell lymphoma, *IVL* intravascular large B-cell lymphoma, *AITL* angioimmunoblastic T-cell lymphoma, *ENKL* extranodal NK/T-cell lymphoma, *PTCL* peripheral T-cell lymphoma, *FL* follicular lymphoma, *MCL* mantle cell lymphoma, *NS* not significant

To determine the staging of lymphomas, a bone marrow aspirate was evaluated for possible lymphoma cell invasion in all lymphoma patients. Regarding the diagnosis of LAHS in the present study, persistent high fever and progressive cytopenia at presentation or on admission prompted us to evaluate the marrow aspirate. As shown in Table [1](#Tab1){ref-type="table"}, abnormal lymphocytes and hemophagocytosis were concomitantly observed. These abnormal lymphocytes were determined as of lymphoid nature by flow cytometry. Because all these patients except for those with intravascular large B-cell lymphoma (IVL; Table [1](#Tab1){ref-type="table"}) had superficial lymphadenopathy at presentation or on admission, a diagnosis of malignant lymphoma and its subtype was established based on pathologic examination of biopsied lymph nodes. Therefore, tentative diagnosis of malignant lymphoma was made based on flow cytometry of bone marrow cells before the final diagnosis by lymph node biopsy in about 50 % of LAHS patients. The final diagnosis of IVL with hemophagocytosis (Table [1](#Tab1){ref-type="table"}) was made based on the presence of lymphoma cells in small vessels in the biopsy specimen of the skin, lung, or bone marrow in addition to the abnormal large lymphocytes in the bone marrow and their phenotype by flow cytometry as described above.

Cytokine assay by CBA {#Sec4}
---------------------

The sera were collected at the time of hospitalization, acute phase, remission after chemotherapy, and follow-up period and kept frozen at −80 °C until analysis. G-CSF, IFN-γ, IL-6, IL-8, IL-10, IP-10, MIG, MIP-1α, and TNF-α in the sera were measured using CBA Flex Set kits (BD Biosciences, San Jose, CA, USA). The minimum detection limits of these kits were 1.6 pg/ml for G-CSF, 0.3 pg/ml for IFN-γ, 1.6 pg/ml for IL-6, 1.2 pg/ml for IL-8, 0.1 pg/ml for IL-10, 0.5 pg/ml for IP-10, 0.2 pg/ml for MIG, 0.2 pg/ml for MIP-1α, and 0.7 pg/ml for TNF-α. The maximum detection limits of all kits were 2,500 pg/ml. When a cytokine concentration exceeded 2,500 pg/ml, diluted sera with an assay diluent were re-assayed. The data were analyzed by FCAP Array Software (BD Biosciences, San Jose, CA, USA).

Statistical analysis {#Sec5}
--------------------

Differences between two or three independent groups were evaluated by Mann--Whitney *U* test and Kruskal--Wallis tests, followed by Dunn's multiple-comparison test, respectively. Analysis of multiple paired data was performed using Friedman's test, followed by Tukey's multiple comparison test. Rank correlation coefficient was determined using Spearman's rank correlation coefficient method. All calculations were carried out using the program JMP 8.0 (SAS Institute Inc., Cary, NC, USA). *P* values of \<0.05 were considered to be significant.

Results {#Sec6}
=======

Patients with or without LAHS {#Sec7}
-----------------------------

As shown in Table [1](#Tab1){ref-type="table"}, reflecting severe clinical features, all indicated parameters (clinical stage, International Prognosis Index, B symptom, white blood cell count, hemoglobin concentration, platelet count, lactate dehydrogenase (LDH), concentration of soluble IL-2 receptor (sIL-2R), and ferritin level) except for subtype proportion of underlying lymphomas and patient's age were significantly different between LAHS and non-LAHS groups. In addition, five of six non-LAHS patients with B symptom had a fever as LAHS patients.

Comparison of serum cytokine concentrations between LAHS, non-LAHS, and normal control groups {#Sec8}
---------------------------------------------------------------------------------------------

As shown in Fig. [1](#Fig1){ref-type="fig"}, serum concentrations of IP-10, MIG, IL-6, IL-10, IFN-γ, and MIP-1α in the LAHS group were significantly higher than those in the non-LAHS group. Of interest, concentrations of IP-10 and MIG in the LAHS group were extremely high, at more than 500 and 5,000 pg/ml, respectively. Meanwhile, serum levels of IL-8, TNF-α, and G-CSF did not significantly differ between the LAHS group and the non-LAHS group (data not shown).Fig. 1Serum cytokine profile in patients with LAHS, non-LAHS, and healthy controls. **a** IP-10, **b** MIG, **c** IL-6, **d** IL-10, **e** IFN-γ, **f** MIP-1α. *NS* not significant

Comparison of serum cytokine concentrations between LAHS and non-LAHS at similar clinical conditions {#Sec9}
----------------------------------------------------------------------------------------------------

Because aggressive non-LAHS is clinically similar to LAHS, we compared cytokine profile between patients with LAHS and non-LAHS patients with advanced clinical stage (stage IV), high international prognostic index (IPI), B symptom, high LDH levels (more than two times of institutional upper limit; 460 IU/L), and bone marrow involvement of the lymphoma. As shown in Table [2](#Tab2){ref-type="table"}, serum concentrations of IP-10 and MIG in LAHS patients were significantly higher than those in non-LAHS patients with these unfavorable parameters, while concentrations of IFNγ in LAHS patients with high LDH did not significantly differ from those in non-LAHS patients with similar parameter, LDH. These results indicate that high serum levels of IP-10 and MIG are characteristic of lymphoma-associated hemophagocytosis.Table 2Comparison of serum concentrations of IP-10, MIG, IFNγ, and IL-6 between LAHS and non-LAHS in unfavorable clinical conditionsParametersLAHSNon-LAHSIP-10: *P* valueMIG: *P* valueIFNγ: *P* valueIL-6Stage IV*n* = 15*n* = 11\<0.01\<0.05\<0.05NSIPI*n* = 14*n* = 6\<0.01\<0.05\<0.05NSB symptom*n* = 15*n* = 7\<0.01\<0.05\<0.05NSLDH (\>460 IU/L)*n* = 10*n* = 4\<0.05\<0.05NSNSBM invasion*n* = 15*n* = 11\<0.01\<0.05\<0.05NSConcentrations of IP-10 and MIG in LAHS patients are significantly higher than those in non-LAHS patients. Concentrations of IFNγ in LAHS patients with high LDH did not significantly differ from those in non-LAHS patients with similar parameter, LDH*LAHS* lymphoma-associated hemophagocytic syndrome, *IPI* International Prognostic Index, *LDH* lactate dehydrogenase, *BM* bone marrow, *NS* not significant

Serum concentrations of IP-10 and MIG at the diagnosis of LAHS and after chemotherapy {#Sec10}
-------------------------------------------------------------------------------------

We then compared serum concentrations of IP-10, MIG, IL-6, IL-10, IFN-γ, and MIP-1α at the diagnosis of LAHS and after chemotherapy. The definition of the time when LAHS was diagnosed was the day when hemophagocytosis was confirmed by bone marrow tap. In addition, all patients with LAHS achieved complete or nearly complete remission after chemotherapy. As shown in Fig. [2](#Fig2){ref-type="fig"}, serum concentrations of IP-10, IL-6, IL-10, and MIP-1α, which were measured at the time of admission, were not significantly different when compared with those at the time of the diagnosis of LAHS, indicating that these levels had already reached a high level when the LAHS clinically manifested itself. Another analysis was the comparison of cytokine concentrations at the time of diagnosis with those at the time of remission after successful chemotherapy. As shown in Fig. [2](#Fig2){ref-type="fig"}, concentrations of IP-10, MIG, IL-10, and IFN-γ were significantly decreased compared with those at the time of diagnosis of LAHS, indicating that these cytokines are useful as markers of therapeutic outcomes. Serum concentrations of IP-10 and MIG in LAHS patients at the time of remission, however, were still significantly higher (*P* \< 0.001 for both chemokines) than those in normal control presumably due to heterogeneous remission conditions including partial remission or post-remission chemotherapy. We could repeatedly measure serum concentrations of these two chemokines in three patients in complete remission after the completion of chemotherapy and found all results to be within normal levels.Fig. 2Changes in serum cytokine concentrations in 12 LAHS patients on three occasions: three time points are on admission, at the time of diagnosis, and during the remission of LAHS. The interval between the time of admission and diagnosis is around 3 days. **a** IP-10, **b** MIG, **c** IL-6, **d** IL-10, **e** IFN-γ, **f** MIP-1α. *NS* not significant

Correlation between serum concentration of IP-10 and MIG {#Sec11}
--------------------------------------------------------

From the findings in the preceding paragraph, we selected IP-10 and MIG as useful markers, and the sensitivity and specificity for the diagnosis of LAHS were 100 and 95 %, respectively, when we set respective values (IP-10 500 pg/ml and MIG 5,000 pg/ml) as the cut-off levels. In addition, we examined the correlation of these two chemokines in LAHS. The concentrations of these two strongly correlated (*R* = 0.732) in LAHS and non-LAHS patients.

The relationship of cytokine concentrations with severity of LAHS {#Sec12}
-----------------------------------------------------------------

We classified LAHS into two groups based on the severity of HPS \[[@CR11]\]. In this setting, we defined severe LAHS as when a patient fulfilled all the following values and the remaining patients as having moderate/mild LAHS: platelet count: below 65 × 10^9^/l, LDH: more than 750 IU/l, sIL-2R: more than 5,000 U/ml, and ferritin: more than 5,000 ng/ml. Figure [3](#Fig3){ref-type="fig"} shows that only IP-10 and MIG could distinguish severe LAHS from moderate/mild LAHS.Fig. 3The relationship of serum cytokine levels to the disease severity in LAHS. **a** IP-10, **b** MIG, **c** IL-6, **d** IL-10, **e** IFN-γ, **f** MIP-1α. *NS* not significant

The difference of cytokine concentrations between B-LAHS and T/NK-LAHS {#Sec13}
----------------------------------------------------------------------

Next, we analyzed whether or not we can distinguish B-LAHS from T/NK-LAHS using cytokine concentrations. Serum concentrations of IP-10, MIG, and IFN-γ were significantly higher (*P* = 0.005, 0.005, and 0.05, respectively) in T/NK-LAHS than in B-LAHS, although the level of significance in IFN-γ was low (*P* = 0.05). Regarding IL-6, IL-10, and MIP-1α, serum levels of these cytokines did not significantly differ between the two groups.

IP-10 and MIG can distinguish LAHS from sepsis {#Sec14}
----------------------------------------------

Because of prominent inflammation in sepsis as in LAHS, we analyzed whether we can distinguish LAHS from sepsis by using blood levels of IP-10 and MIG. In this analysis, we compared serum concentrations of IP-10 and MIG in LAHS with those in nine patients with hematologic malignancies, who developed sepsis. As shown in Fig. [4](#Fig4){ref-type="fig"}, serum concentrations of IP-10 and MIG in sepsis patients were significantly low compared with those in LAHS (*P* \< 0.001).Fig. 4Comparison between serum concentrations of IP-10 and MIG in LAHS patients and those in patients with hematologic malignancies complicated with sepsis. **a** IP-10, **b** MIG, **c** IL-6, **d** IL-10, **e** IFN-γ, **f** MIP-1α. *NS* not significant

Discussion {#Sec15}
==========

In the present study, we identified IP-10 and MIG as being useful markers for both the diagnosis of LAHS and therapeutic outcomes for the following reasons: (1) serum concentrations of these two chemokines at the time of LAHS diagnosis were extremely high compared with those of other examined cytokines; (2) the concentrations of these two chemokines significantly decreased after successful chemotherapy; (3) importantly, the scattering amplitude of values for these two chemokines at three occasions was small (Fig. [2](#Fig2){ref-type="fig"}) compared with that in other cytokines, including IFN-γ and IL-10, which varied widely; and (4) the sensitivity and specificity for the diagnosis of LAHS were 100 and 95 %, respectively, when we set the cut-off values of IP-10 (500 pg/ml) and MIG (5,000 pg/ml) at the LAHS diagnosis. Thus, these two chemokines could be reliable markers for both diagnosis of LAHS and its therapeutic outcomes. In the present study, we included five patients with follicular lymphoma (FL) in non-LAHS group that is one of controls to LAHS group. Although FL is an indolent lymphoma, mean serum concentrations of IP-10 (434.2 pg) and MIG (3,221.1 pg) in patients with FL were comparable to those of IP-10 (417.0 pg) and MIG (2,580.1) in patients with non-FL (*n* = 13), respectively. Therefore, it is unlikely that FL affected cytokine levels of IP-10 and MIG in non-LAHS group because of its indolence.

IP-10 and MIG appeared also to be useful in distinguishing both severe LAHS from moderate/mild LAHS and T/NK-LAHS from B-LAHS. It was interesting that serum levels of these two chemokines in T/NK-LAHS were higher than those in B-LAHS, possibly reflecting higher cytokine production in T/NK neoplasms than in B-cell tumors. Furthermore, these two chemokines were also useful to distinguish LAHS from sepsis in which blood levels of multiple inflammatory cytokines are elevated \[[@CR34]--[@CR39]\]. From the findings described above, both IP-10 and MIG are considered to be specific to many aspects of LAHS.

The major producers of IP-10 and MIG are IFN-γ-activated macrophages \[[@CR40]--[@CR42]\]. Among these activated macrophages, resident macrophages more strongly express IP-10 than those derived from monocytes \[[@CR43]\]. Neutrophils produce these two chemokines \[[@CR44]\], and dendritic cells and endothelial cells also express IP-10 and MIG, respectively \[[@CR45], [@CR46]\]. Importantly, IP-10 and MIG are chemo-attractants for activated T cells, especially Th1 cells that produce IFN-γ \[[@CR47]--[@CR49]\]. Therefore, IP-10 and MIG, which are produced by IFN-γ-activated macrophages, attract Th1 cells through CXCR3 toward activated macrophages \[[@CR48]--[@CR50]\]. These mobilized Th1 cells produce IFN-γ and further activate macrophages to produce both IP-10 and MIG. This loop may explain the high blood levels of IP-10 and MIG during LAHS.

IFN-γ has been supposed to be one of the major mediators of LAHS \[[@CR20], [@CR22]\]. However, its blood level was low during LAHS in the present study. Furthermore, IFN-γ was not a good marker for the diagnosis of LAHS. In the loop supposed in the previous paragraph, IFN-γ production by Th1 cells should be enhanced by persistent recruitment of Th1 cells toward macrophages. Although the reason for this remains to be elucidated, migrated Th1 cells might be able to activate the loop even with a small amount of IFN-γ because Th1 cells are mobilized close to macrophages. In other words, IFN-γ may play a role as a trigger for the loop. Therefore, the present study does not rule out the possible central role of IFN-γ in LAHS. Rather, it is possible to assert that the initiator of LAHS is not always a good marker for LAHS.

LAHS may be initiated by cytokines derived from lymphoma cells, which activate macrophages in a direct or indirect fashion. As a direct mediator, IFN-γ is the most likely cytokine. As an indirect mediator, TNF-α, IL-1, or IL-2 is a possibility. In this fashion, these cytokines activate T cells to produce IFN-γ. However, the production of these cytokines by lymphoma cells in LAHS has not been studied. In Hodgkin's lymphoma, the expression of IP-10, MIG, or IFN-γ was previously reported \[[@CR50]\]. Although this is an interesting finding, it is unclear whether these cytokines are directly produced by tumor cells.

In conclusion, we have shown specifically high blood levels of IP-10 and MIG in LAHS as well as a strong correlation between concentrations of these chemokines and clinical status for the first time. We also demonstrated the usefulness of CBA in terms of rapid measurement of these chemokines, which leads to early and proper diagnosis of LAHS. Further studies are needed to elucidate the exact role of IP-10 and MIG in the pathophysiology of LAHS.
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